['hypercholesterolemia', 'atherosclerosis', 'statin adverse reaction']
['bempedoic acid', 'ezetimibe']

        Inclusion Criteria:

          -  Fasting LDL-cholesterol greater than or equal to 100 mg/dL at screening

          -  Men and nonpregnant, nonlactating women

          -  Use of stable lipid-modifying therapy for at least 4 weeks prior to screening that
             includes ezetimibe 10mg daily

        Exclusion Criteria:

          -  Fasting blood triglycerides greater than or equal to 500 mg/dL

          -  Body Mass Index (BMI) greater than or equal to 50 kg/m2

          -  Recent history of clinically significant cardiovascular disease

          -  Use of statin therapy where doses are greater than those defined as "low-dose" within
             4 weeks prior to screening; where "low-dose" is defined as an average daily dose of
             rosuvastatin 5 mg, atorvastatin 10 mg, simvastatin 10 mg, lovastatin 20 mg,
             pravastatin 40 mg, fluvastatin 40 mg, or pitavastatin 2 mg.
      